A survey evaluating surgeons' perioperative usage of acetyl-salicylic acid (ASA) and their willingness to enroll their patients in a perioperative ASA randomized controlled trial Abstract Purpose: Major cardiovascular complications associated with noncardiac surgery represent a substantial population health problem for which there are no established e cacious and safe prophylactic interventions. Acetyl-salicylic acid (ASA) represents a promising intervention. e objective of this study was to determine surgeons' perioperative usage of ASA, and if they would enroll their patients in a perioperative ASA randomized controlled trial (RCT).
Among the 200 million adults worldwide who undergo major noncardiac surgery annually, several million will su er a major perioperative vascular complication (vascular death, nonfatal myocardial infarction, nonfatal cardiac arrest, or nonfatal stroke) [1, 2] . We recently completed the PeriOperative ISchemic Evaluation (POISE-1) Trial that randomized 8351 patients in 190 centres in 23 countries to extended-release metoprolol succinate (metoprolol CR) or placebo around the time of noncardiac surgery [3] . e POISE-1 Trial demonstrated that metoprolol CR prevented myocardial infarctions but increased the risk of stroke and death. ese negative consequences of perioperative beta-blockers were unsuspected prior to POISE-1, highlighting the importance and need for large randomized controlled trials (RCTs) in the perioperative setting.
In the non-operative setting, acetyl-salicylic acid (ASA) reduces nonfatal myocardial infarction by one third, nonfatal stroke by one quarter, and vascular mortality by one sixth in patients with, or at risk of, atherosclerotic disease [4] . Immediately a er noncardiac surgery, patients experience a rise in circulating platelet release products [5] . Platelet surface catalyzing coagulation reactions facilitate thrombin generation and these events may promote thrombus formation and lead to arterial occlusion in the perioperative setting [6] . Acute withdrawal of chronic ASA results in a pro-thrombotic state (i.e., increased thromboxane A2 and decreased brinolysis) [7, 8] . Given these physiological changes, ASA initiation or, for chronic users, ASA continuation -and the associated inhibition of platelet aggregation -may prevent major perioperative vascular events [9] .
Despite the compelling physiological arguments for the use of ASA therapy in patients undergoing noncardiac surgery, the RCT evidence is limited and con icting. A systematic review of antiplatelet therapy versus placebo in patients undergoing infrainguinal bypass surgery identi ed 10 RCTs, of which six evaluated the e ects of ASA [10] . is review included a total of 168 vascular events (i.e., vascular death, nonfatal myocardial infarction, or nonfatal stroke) among 1765 patients and demonstrated a trend towards fewer events with ASA (OR=0.76; 95% CI 0.54 to 1.05). In contrast, a hip fracture surgery trial, the Pulmonary Embolism Prevention (PEP) Trial, reported 105 ischemic cardiac events (i.e., death due to ischemic heart disease or nonfatal myocardial infarction) among the 6677 patients randomized to ASA and 79 ischemic cardiac events among the 6677 patients randomized to placebo (HR=1.33; 95% CI 1.00 to 1.78) [11] . ASA did, however, prevent pulmonary emboli (HR=0.43; 95% CI 0.18 to 0.60).
ASA therapy in patients undergoing noncardiac surgery is associated with a higher risk of bleeding, but the magnitude of this risk is uncertain. In the PEP Trial, there were 197 postoperative bleeding episodes requiring a transfusion in the ASA group in comparison with157 such events in the placebo group (RRI=24%; 95% CI 1 to 53%) [11] . In the Antiplatelet Trialists overview of RCTs in surgical patients (ASA was the intervention in 1/3 of these trials), there were 28 nonfatal bleeding episodes requiring a transfusion among the 3798 patients randomized to antiplatelet therapy and 15 among the 3808 patients randomized to control (p=0.04) [12] .
e clear evidence that ASA prevents cardiovascular events in the non-perioperative setting, the physiological rationale for the use of ASA in patients undergoing noncardiac surgery, the con icting RCT evidence surrounding the impact of ASA on perioperative cardiovascular events, and the imprecision regarding the increased risk of bleeding associated with perioperative ASA, together argue for a large de nitive RCT of ASA therapy in patients undergoing noncardiac surgery. Prior to undertaking such a trial, it is important to establish feasibility: the feasibility of a perioperative ASA trial is dependent upon surgeons' willingness to allow their patients to participate. To inform this issue, we undertook a survey of surgeons' current practice patterns of perioperative ASA, and their interest in having their patients participate in a perioperative ASA RCT.
Methods
A self-administered mail survey was conducted with Canadian surgeons. Given that 84% of the patients in the POISE-1 Trial underwent general, orthopedic, or vascular surgery, the survey was restricted to these surgeons. All members of the Canadian Association of General Surgeons, Canadian Orthopaedic Association, and the Canadian Society of Vascular Surgeons were eligible to participate in our survey. The surgeons' mailing addresses were obtained from these organizations. e survey was designed to elicit surgeons' self-reported current use of perioperative ASA, and their willingness to have their patients participate in a perioperative ASA RCT. Research team members, comprised of two surgeons, two internists and one cardiologist, generated items for the survey, discussed format and response options, and reviewed multiple iterations of the survey.
Respondent characteristics were recorded. Surgeons were asked to only consider their patients who were > 45 years of age, with, or at risk of, atherosclerotic disease, and undergoing noncardiac surgery requiring a general or regional anaesthetic and an overnight hospital stay. These patients represent the eligibility criteria that would be used in a large trial. Surgeons were asked a series of questions related to their patients who were already taking chronic ASA and a series of questions related to their patients who were not taking chronic ASA. Our survey was one page long, as research demonstrates that higher physician response rates are associated with shorter surveys [13] . e nal survey is given in the Appendix.
Four general surgeons, nine orthopedic surgeons, and six vascular surgeons assessed the clinical sensibility of our survey instrument using a ve point Likert scale, with responses ranging from 1 (negative), 3 (positive), to 5 (extremely positive). Median scores for the six domains evaluated were: face validity (4), content validity (3), clarity (4), utility (4), redundancy (5), and discriminability (3).
e survey was pretested prior to administration.
The survey was mailed to eligible surgeons and was resent to non-responders at four, eight, and 12 weeks after the first mail out. Test-retest reliability of the survey was evaluated by 54 surgeons at eight weeks (range of kappa values 0.49-0.93).
The surgeon response rate was determined. For each survey item, the proportion of surgeon respondents who selected each response was calculated.
a large perioperative ASA trial was deemed to be feasible if surgeons indicated that they would allow > 41% of their patients to participate in that trial. A survey response rate > 45%, which would represent at least 834 respondents, was required to adequately inform the feasibility of a large ASA trial. is was based upon the assumption that general, orthopedic, and vascular surgeons would have at least one patient per week (a conservative estimate based on our research) with or at risk of atherosclerotic disease upon whom they perform major noncardiac surgery. If surgeons allowed at least 41-60% (i.e., an average of 50%) of their patients to participate in a perioperative ASA trial, and if 50% of these patients consented, 208 patients could be recruited per week. Even if only 50% of these centres participated in the trial, 104 patients could still be recruited per week. Given that there are at least 42 weeks in a year for recruiting patients, 10,000 patients could be recruited in Canada within a 2.4-year period (i.e., a feasible period of time).
The survey data were analyzed using the Statistical Package for the Social Science (SPSS) version 10.0 software. Results Table 1 reports the response rate and respondent characteristics. A total of 1854 surgeons were surveyed and 906 completed and retuned the survey, a response rate of 49%. A majority of respondents (i.e., 60%) worked in a university or university-affiliated hospital. Table 2 reports surgeons' knowledge of their patients ASA usage prior to surgery. A majority of general and vascular surgeons reported awareness of whether 50% or more of their patients were or were not taking ASA prior to surgery. Over half of the orthopedic surgeons reported awareness of use of ASA prior to surgery in 40% or less of their patients. Two orthopedic surgeons did not know about ASA usage in any of their patients prior to surgery; these surgeons were only able to provide data on their willingness to allow their patients to participate in an ASA trial.
Respondents were asked four questions about their practice regarding their patients who were taking ASA chronically. A majority of general surgeons (69%) and orthopedic surgeons (73%) had less than 40% of their patients continue ASA prior to surgery, whereas a majority of vascular surgeons (76%) continued > 81% of their patients on ASA prior to surgery (Table 3) . Of respondents who had patients stop ASA, the majority did so > 4 days prior to surgery. For patients taking ASA chronically prior to surgery, a majority of general (67%), orthopedic (59%), and vascular (86%) surgeons had their patients restart ASA after surgery (Table 4 ). For patients who had ASA restarted after surgery, a majority of vascular surgeons (73%) restarted on day one after surgery, whereas 43% of orthopedic surgeons had patients restart ASA > 4 days after surgery.
A majority of general surgeons (70%) and orthopedic surgeons (82%) had none of their patients start ASA prior to surgery, whereas a minority of vascular surgeons (13%) had none of their patients start ASA prior to surgery (Table 5) . Respondents reported widely variable approaches as to when they had patients start ASA prior to surgery (Table 5 ). For patients not taking ASA chronically prior to surgery, a majority of vascular surgeons (52%) had > 81% of their patients start ASA after surgery, whereas a minority of general surgeons (2%) and orthopedic surgeons (3%) had > 81% of their patients start ASA after surgery (Table 6 ). There was substantial variation as to when respondents had patients start ASA after surgery (Table 6 ).
Considering patients taking ASA chronically, 73% of the general surgeons, 70% of the orthopaedic surgeons, and 36% of the vascular surgeons would allow > 41% of their patients to participate in a perioperative RCT comparing continuing versus stopping ASA, Table 7 . Considering patients not taking ASA chronically, 76% of the general surgeons, 67% of the orthopaedic surgeons, and 51% of the vascular surgeons would allow > 41% of their patients to participate in a perioperative RCT comparing starting ASA versus placebo.
Discussion
All Canadian general, orthopedic, and vascular surgeons (total sample 1854 surgeons) were surveyed to ascertain their perioperative usage of ASA and willingness to have their patients participate in a perioperative ASA trial; 906 (49%) surgeons completed our survey. Surgeons reported substantial practice pattern variation regarding their perioperative management of ASA. A majority of surgeons were willing to allow > 41% of their patients to participate in a perioperative ASA RCT.
is Study
Strengths of our study include the national perspective obtained by surveying all Canadian general, orthopedic, and vascular surgeons about a topical, potentially effective, and available intervention that could impact favourably on perioperative morbidity and mortality. Rigorous survey methods were used [14] . Our survey instrument demonstrated good clinical sensibility on testing in six domains (face validity, content validity, clarity, utility, redundancy, and discriminability); and the test-retest reliability of the survey among 54 surgeons at eight weeks was satisfactory. Limitations include the response rate of only 49%. This response rate did, however, provide enough respondents to assess the feasibility of a large perioperative ASA trial using our criteria. Furthermore, our response rate is similar to most physician-mailed surveys [15] . Based on the results of this study, surgeons in Canada report no uniform approach to ASA use prior to noncardiac surgery. When surgeons were asked to consider patients who were taking ASA chronically, there was wide variation in practice patterns related to stopping ASA amongst the general and orthopaedic surgeons, whereas the majority of vascular surgeons continued ASA preoperatively. In addition, there was no consensus on which preoperative day to discontinue ASA. A majority of surgeons (i.e., general 67%, orthopedic 59%, vascular 86%) restarted ASA after surgery in > 81% of their patients who had a history of taking ASA chronically. Variability was marked regarding when ASA was restarted except among vascular surgeons among whom 73% started on day one after surgery. When focusing on patients not taking ASA prior to surgery who are at risk for a perioperative cardiovascular events, the majority of general (70%) and orthopaedic (82%) surgeons would not start ASA prior to surgery, whereas vascular surgeons demonstrated marked variability in their responses. There was substantial variability regarding the proportion of patients the various surgical groups would restart ASA in after surgery and the timing of starting ASA prior to and after surgery.
Combining surgeon responses across all surgical groups and for all patients (including those both taking and not taking ASA 
years).
Conclusion is national survey of surgeons' self-reported attitudes and practice patterns shows variable perioperative ASA usage. Until clear evidence from a large high-quality RCT is available these marked variations in practice patterns are likely to persist. Our survey identi es the need for, and interest in, a large randomized trial of perioperative ASA among patients undergoing noncardiac surgery.
